Anti-tuberculosis Therapeutics Market was valued at US $1,344.85 million in 2021 and is projected to grow at 6.21% CAGR over the forecast period to reach US $1,930.02 million by 2027. Anti-tuberculosis Therapeutics Market represented US $152.57 million opportunity over 2019-2021 and estimated to create US $585.17 million opportunity in 2027 over 2021.
Anti-tuberculosis Therapeutics from Consainsights analyses the Anti-tuberculosis Therapeutics Market in the Life Sciences industry over the forecast period to 2027.
Anti-tuberculosis Therapeutics research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.
Anti-tuberculosis Therapeutics segmentation includes Drug Class, End User and Geography.
Based on the Drug Class, the Anti-tuberculosis Therapeutics analysis covers Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Amynoglycosides, Thioamides, Cyclic Peptides, Other Drug Classes.
In Drug Class segment, Isoniazid segment has highest cagr growth of 5.50%.
Based on the End User, the Anti-tuberculosis Therapeutics analysis covers Hospitals and Clinics, Government Agencies, Non Profit Organizations, Other End Users.
In End User segment, Government Agencies segment has highest cagr growth of 5.50%.
Based on the region, the Anti-tuberculosis Therapeutics analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.
Key companies operating in the market include Lupin Limited, Macleods Pharmaceuticals Ltd, Otsuka Pharmaceutical Co. Ltd, Johnson and Johnson, Pfizer Inc., Novartis AG and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.